MétaCan
Menu
Back to cohort
Record W2794357230 · doi:10.1093/jcag/gwy008.252

A251 TC-325 USE IN MALIGNANT UPPER GASTROINTESTINAL BLEEDS: A MULTICENTRE RETROSPECTIVE STUDY

2018· article· en· W2794357230 on OpenAlexaffabout
Kaleb J. Marr, Zhao Wu Meng, Rachid Mohamed, Paul D. James

Bibliographic record

VenueJournal of the Canadian Association of Gastroenterology · 2018
Typearticle
Languageen
FieldMedicine
TopicGastrointestinal Bleeding Diagnosis and Treatment
Canadian institutionsUniversity of OttawaUniversity of Calgary
Fundersnot available
KeywordsMedicineHemostasisUpper gastrointestinal bleedingClinical endpointRetrospective cohort studySurgeryEndoscopyClinical trialInternal medicine

Abstract

fetched live from OpenAlex

TC-325 has recently been proposed as a potential therapeutic agent for use in traditionally difficult to treat malignant upper gastrointestinal bleeds (UGIB). The aim of this study is to assess the proportion of patients with malignant UGIB treated with either TC-325 alone or in combination with conventional therapy that achieve long-term hemostasis. This is a multicentre retrospective study at the University of Calgary and University of Ottawa assessing the efficacy of TC-325 in achieving hemostasis in malignant UGIB between January 1, 2010 and July 30, 2016. TC-325 use was identified via staff polling, product order forms, and endoscopic records review. Once identified, patient charts and online records (Sunrise Clinical Manager, Calgary; vOACIS, Ottawa) were reviewed to identify those with malignant UGIB and to assess our primary and secondary endpoints. The primary outcome was hemostasis at 7 days. Secondary outcomes include immediate hemostasis, the need for repeat endoscopy, surgical intervention, transarterial embolization, and 30-day mortality. TC-325 was utilized for malignant UGIB in 19 patients. The median age was 68 (IQR 57–78), 11 were males (58%). Fifteen patients (79%) were Forrest Classification 1B with a median Blatchford score of 11 (IQR 7–12). TC-325 was utilized as the primary modality for hemostasis in 15 patients (79%). Eighteen patients (95%) achieved immediate hemostasis post-TC-325 and 8 patients (42%) eventually rebled after this. Three patients (16%) had recurrent bleeding within 24 hours. Only 13 patients had sufficient data to examine our primary endpoint of 7 days and 4 (31%) rebled by that time (all in Calgary). Three patients died before 7 days and 3 changed their goals of care. At 14 days, 3 patients (25%) rebled. A repeat endoscopy was required in 7 patients (37%). Two patients (11%) required surgical intervention. Transarterial embolization was not required. Ten patients died by 30 days (53%); one due to perforation of their malignant ulcer and another from an uncontrollable malignant UGIB. There were no complications directly associated with TC-325. This is the first multicenter study evaluating 7-day hemostasis when TC-325 is used in malignant UGIB. TC-325 is effective at immediate and early hemostasis. However, rebleeding risk is increased by day 7 post-treatment. TC-325 may be utilized to immediately achieve hemostasis. Up to a third of patients may require another definitive intervention to achieve long-term hemostasis. None

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.027

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.251
Teacher spread0.236 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes2
Has abstractyes

Explore more

Same venueJournal of the Canadian Association of GastroenterologySame topicGastrointestinal Bleeding Diagnosis and TreatmentFrench-language works237,207